EE333 Evaluating the Long-Term Clinical, Societal, and Economic Outcomes of Ofatumumab vs Teriflunomide/Interferon Β-1A and the Impact of Early vs Delayed Ofatumumab Initiation in Relapsing Multiple Sclerosis Patients in Greece
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.579
https://www.valueinhealthjournal.com/article/S1098-3015(22)02783-8/fulltext
Title :
EE333 Evaluating the Long-Term Clinical, Societal, and Economic Outcomes of Ofatumumab vs Teriflunomide/Interferon Β-1A and the Impact of Early vs Delayed Ofatumumab Initiation in Relapsing Multiple Sclerosis Patients in Greece
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02783-8&doi=10.1016/j.jval.2022.09.579
First page :
Section Title :
Open access? :
No
Section Order :
10107